All In Biotech

Drug Trial Radar · NCT07889193

Phase I Clinical Trial of Trivalent Inactivated Split Influenza Virus Vaccine (MDCK Cell)

A Randomized, Double-Blind, Placebo and Positive-Controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Trivalent Inactivated Split Influenza Virus Vaccine (MDCK Cell) in Participants Aged 6 Months and Above

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 175 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

175

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Dec 2026

Study completion May 2027

Sponsor

Lead sponsor
Sinovac Biotech Co., LtdIndustry
Sponsor type
Industry
First posted
Oct 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a phase I, randomized, double-blind, placebo and active comparator-controlled clinical trial to evaluate the safety and immunogenicity of a trivalent split influenza virus vaccine (MDCK cell) developed by Sinovac Biotech Co., Ltd., in participants aged 6 months and above.

Conditions

  • Seasonal Influenza

Interventions

  • Cell-based Trivalent Split Influenza Virus Vaccine (cTIV)Biological

    Investigational trivalent split influenza virus vaccine produced in MDCK cells, administered intramuscularly.

  • Egg-based Trivalent Split Influenza Virus Vaccine (eTIV)Biological

    Licensed trivalent split influenza virus vaccine (Anflu) produced in embryonated chicken eggs, administered intramuscularly.

  • PlaceboOther

    0.9% normal saline for intramuscular injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse reactionsTime frame: 0-28 days after each dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial Center for Disease Control and Prevention (Guangdong Academy of Preventive Medical Sciences)

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.